undamentalytics Newsletter
Sign in

Annovis Bio, Inc. income statement

In fiscal 2025, Annovis Bio, Inc. reported revenue of $0 and net income of −$28.9m, or −$1.40 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue00000000
Research and development1381739202544
General and administrative14696746
Operating income−2−7−15−26−45−27−30−50
Income before tax−1−5−14−25−56———
Income tax0—————00
Net income−1−5−14−25−56−25−29−50
Diluted EPS−$3.51−$0.87−$1.90−$3.10−$6.23−$2.31−$1.40−$1.79
Diluted shares (average)—6m8m8m9m12m21m28m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Annovis Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Annovis Bio, Inc.